Trial reportJAMA2011
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.
Trial report in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 110 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
Who cites it
110 citing papers in PubMed, 3 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Inhaled nitric oxide for treating pain crises in people with sickle cell disease.The Cochrane database of systematic reviews · 2022Pooled it
- Drugs for preventing red blood cell dehydration in people with sickle cell disease.The Cochrane database of systematic reviews · 2018Pooled it
- Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis.Internal and emergency medicine · 2015Pooled it
- Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.The Lancet. Haematology · 2024Trial
- Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism.Nitric oxide : biology and chemistry · 2020Trial
- Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial.Nitric oxide : biology and chemistry · 2019Trial
- A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).American journal of hematology · 2018Trial
- Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.American heart journal · 2017Trial
- Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study.Intensive care medicine · 2015Trial
- Trial
- A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.Haematologica · 2013Trial
- A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.Thrombosis research · 2013Trial
- IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.Clinical trials (London, England) · 2013Trial
- Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial.Contemporary clinical trials · 2012Trial
- Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease.Antibodies (Basel, Switzerland) · 2026Review
- Review
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Public-private partnerships in tackling sickle cell disease in Uganda: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease.Annals of intensive care · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 1 institution in 1 country.
Funding
Abstract
contextInhaled nitric oxide has shown evidence of efficacy in mouse models of sickle cell disease (SCD), case series of patients with acute chest syndrome, and 2 small placebo-controlled trials for treatment of vaso-occlusive pain crisis (VOC).
objectiveTo determine whether inhaled nitric oxide gas reduces the duration of painful crisis in patients with SCD who present to the emergency department or hospital for care. DESIGN, SETTING, AND
participantsProspective, multicenter, double-blind, randomized, placebo-controlled clinical trial for up to 72 hours of inhaled nitric oxide gas vs inhaled nitrogen placebo in 150 participants presenting with VOC of SCD at 11 centers between October 5, 2004, and December 22, 2008. Intervention Inhaled nitric oxide gas vs inhaled nitrogen placebo.
main outcome measuresThe primary end point was the time to resolution of painful crisis, defined by (1) freedom from parenteral opioid use for 5 hours; (2) pain relief as assessed by visual analog pain scale scores of 6 cm or lower (on 0-10 scale); (3) ability to walk; and (4) patient's and family's decision, with physician consensus, that the remaining pain could be managed at home.
resultsThere was no significant change in the primary end point between the nitric oxide and placebo groups, with a median time to resolution of crisis of 73.0 hours (95% confidence interval [CI], 46.0-91.0) and 65.5 hours (95% CI, 48.1-84.0), respectively (P = .87). There were no significant differences in secondary outcome measures, including length of hospitalization, visual analog pain scale scores, cumulative opioid usage, and rate of acute chest syndrome. Inhaled nitric oxide was well tolerated, with no increase in serious adverse events. Increases in venous methemoglobin concentration confirmed adherence and randomization but did not exceed 5% in any study participant. Significant increases in plasma nitrate occurred in the treatment group, but there were no observed increases in plasma or whole blood nitrite.
conclusionAmong patients with SCD hospitalized with VOC, the use of inhaled nitric oxide compared with placebo did not improve time to crisis resolution.
trial registrationclinicaltrials.gov Identifier: NCT00094887.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.